SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.62+1.6%Dec 31 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BostonView who wrote (10541)6/26/1999 8:26:00 AM
From: Robert K.  Read Replies (1) of 17367
 
BostonView, There are some good observations and not so good observations on his post. Regarding enormus potential, he is potentially way off base, then again perhaps not. If he thinks enormus potential is 500mil, than you can probably claim that for hu1124 alone.
Or even mycoprex alone. Even then 500mil might be way off too on those products. A novel ,safe, cidal,oral ,antifungal, that synergizes
fluconazole and amphoteracin?????? (if it works)..... Duh.......
For bpi potential one can refer to the endotoxin paper. That paper is a biased paper regarding bpi's endotoxin neutralization potentials.(alone)
Of course potential is JUST potential at this juncture. If, and let me repeat IF (IF) bpi comes in, we are potentially (potentially) looking at a product that might reshape medicine a bit. I do not claim it does work, I do not claim it will work, I do not claim it will reshape medicine.
I do think it has possibilities. Standard disclaimers always apply.
All IMO. (consider worthless)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext